Tetracyclic heterocycle compounds useful as HIV integrase inhibitors
The present invention relates to Tetracyclic Heterocycle Compounds of Formula and pharmaceutically acceptable salts or prodrug thereof, wherein A, X, R 1 , R 2 , R 3 and Ware as defined herein. The present invention also relates to compositions comprising at least one Tetracyclic Heterocycle Compound, and methods of using the Tetracyclic Heterocycle Compounds for treating or preventing HIV infection in a subject.
1. A method for the treatment of infection by HIV or for the treatment, or delay in the onset or progression of AIDS in a subject in need thereof, which comprises administering to the subject an effective amount of a compound having the structure:
or a pharmaceutically acceptable salt thereof, and doravirine, or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 comprising
or a pharmaceutically acceptable salt thereof, and doravirine, or a pharmaceutically acceptable salt thereof.
3. The method of claim 1 comprising
or a pharmaceutically acceptable salt thereof, and doravirine, or a pharmaceutically acceptable salt thereof.
4. The method of claim 1 comprising
or a pharmaceutically acceptable salt thereof, and doravirine, or a pharmaceutically acceptable salt thereof.
5. The method of claim 1 comprising
or a pharmaceutically acceptable salt thereof, and doravirine, or a pharmaceutically acceptable salt thereof.
6. The method of claim 1 comprising
or a pharmaceutically acceptable salt thereof, and doravirine, or a pharmaceutically acceptable salt thereof.
7. The method of claim 1 comprising
or a pharmaceutically acceptable salt thereof, and doravirine, or a pharmaceutically acceptable salt thereof.
8. A method for the treatment of infection by HIV or for the treatment, or delay in the onset or progression of AIDS in a subject in need thereof, which comprises administering to the subject an effective amount of a compound having the structure:
or a pharmaceutically acceptable salt thereof, and 4′-ethynyl-2-fluoro-2′-deoxyadenosine, or a pharmaceutically acceptable salt thereof.
9. The method of claim 8 comprising
or a pharmaceutically acceptable salt thereof, and 4′-ethynyl-2-fluoro-2′-deoxyadenosine, or a pharmaceutically acceptable salt thereof.
10. The method of claim 8 comprising
or a pharmaceutically acceptable salt thereof, and 4′-ethynyl-2-fluoro-2′-deoxyadenosine, or a pharmaceutically acceptable salt thereof.
11. The method of claim 8 comprising
or a pharmaceutically acceptable salt thereof, and 4′-ethynyl-2-fluoro-2′-deoxyadenosine, or a pharmaceutically acceptable salt thereof.
12. The method of claim 8 comprising
or a pharmaceutically acceptable salt thereof, and 4′-ethynyl-2-fluoro-2′-deoxyadenosine, or a pharmaceutically acceptable salt thereof.
13. The method of claim 8 comprising
or a pharmaceutically acceptable salt thereof, and 4′-ethynyl-2-fluoro-2′-deoxyadenosine, or a pharmaceutically acceptable salt thereof.
14. The method of claim 8 comprising
or a pharmaceutically acceptable salt thereof, and 4′-ethynyl-2-fluoro-2′-deoxyadenosine, or a pharmaceutically acceptable salt thereof.